CDK9-IN-41

• Description :

  CDK9-IN-41 is a potent CDK9, EGFR, HER2, and COX-2 kinases inhibitor with IC50s of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM. COX-2-IN-18 exhibits remarkable antitumor activity against leukemia cancer cells, colon cancer cells, melanoma cells, ovarian cells and breast cells[1].

• UNSPSC :

  12352005

• Target :

  CDK; COX; EGFR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cox-2-in-18.html

• Purity :

  98.84

• Solubility :

  10 mM in DMSO

• Smiles :

  O=S(C1=CC=C(CCN2C(SCC)=NC3=C(C=CC=C3)C2=O)C=C1)(N)=O

• Molecular Formula :

  C18H19N3O3S2

• Molecular Weight :

  389.49

• References & Citations :

  [1] El-Azab AS, et al. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorg Chem. 2020;104:104345.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK9; COX-2; EGFR/ErbB1/HER1; ErbB2/HER2

• CAS Number :

  [1038061-96-9]